An observational study in Lung Transplant Failure and Rejection and Lung Transplant Infection, sponsored by Jesper Magnusson. Recruiting at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-16.
Sponsored by Jesper Magnusson · Observational
LTx has the shortest survival of all solid organ transplants. The complex and time-demanding diagnostics of allograft dysfunction are a significant reason for this.
The current study aims overarchingly to improve survival after lung transplantation (LTx) through precise and fast diagnostics. The specific aim is to develop direct-to-clinical implementation biomarkers for the most important aspects of long-term survival after LTx. An in-house-developed PCR-based cell-free-DNA methodology (cf-DNA) will be used for allograft damage and combined with specific other biomarkers to identify damage type. The current clinical golden standard for damage identification will be performed at every sampling instance.
The research will be a single-centre prospective observational cohort study. The control samples at all time points will consist of the samples without allograft damage. Blood will be drawn at fixed time points and clinical events. All analyses will be performed at a separate lab, blinded to the patient's status.
.
50 studies on the registry are indexed under Rejection, Psychology; 27 are open to participants now.
This study's planned enrollment of 146 is below the median of 188 across 25 observational studies indexed under Rejection, Psychology.
Browse Rejection, Psychology studies →This is the only study on the registry with Jesper Magnusson as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Newly lung transplanted patients within scandinavia
A good understanding to read and write within the languages in which the consent is provided.
Exclusion Criteria:
No good understanding to read and write within the languages in which the consent is provided.
All eligible patients were transplanted and followed up within the catchment area of the participating centre.
Diagnostic Test: cell-free dNA
Blood samples taker per protocol, analyses performed by a lab blinded to the status of the respective patients
Damage distinction
Null hypothesis: Levels of Cf-DNA is not different at samples taken with allograft damage and no allograft damage.
Time frame: One month, three months, one year, three years, five years
Damage detection Limit
If the null hypothesis is disproven, measure optimal cut off for distincition beteween samples indicating damage and not indicating damage. Also distinction between different types of damage, finally if distinction is attainable trhough association wit other known biomarkers.
Time frame: One month, three months, one year, three years, five years
Plan to share: Yes
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.